Publications by authors named "G Persson Brobert"
Background: Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk.
Objectives: To compare incidence of rVTE, major bleeding, and all-cause mortality for rivaroxaban versus low molecular weight heparin (LMWH) in patients with CAT.
Methods: We developed a cohort study using Swedish national registers 2013-2019.
Objectives: To describe opportunities and challenges experienced from the four pharmacoepidemiological database studies included in the rivaroxaban post authorisation safety study (PASS) programme and propose ways to maximise the value of population-based observational research when addressing regulatory requirements.
Design: PASS programme of rivaroxaban carried out as part of the regulatory postapproval commitment to the European Medicines Agency.
Setting: Clinical practice in Germany, the Netherlands, Sweden and the UK (electronic health records)-undertaken by pharmacoepidemiology research teams using country-specific databases with different coding structures.
Background: The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice.
Methods: Cohorts were created using electronic healthcare databases from the UK, the Netherlands, Germany and Sweden. Patients with a first prescription of rivaroxaban or vitamin K antagonist during the period from December 2011 (in the UK, January 2012) to December 2017 (in Germany, December 2016) for venous thromboembolism indication, with no record of atrial fibrillation or recent cancer history, were observed until the occurrence of each safety outcome (hospitalization for intracranial, gastrointestinal, urogenital or other bleeding), death or study end (December 2018; in Germany, December 2017).
Article Synopsis
- A study examined the effectiveness of rivaroxaban compared to low-molecular-weight heparins (LMWHs) in treating cancer-associated venous thromboembolism (CT) among patients not at high risk of bleeding.
- Researchers analyzed data from over 2,200 patients, monitoring them for 12 months and finding no significant difference in the rates of VTE recurrences, major bleeding, and overall mortality between the two treatment groups.
- The findings suggest that rivaroxaban is a safe and effective alternative to LMWH for treating CT, reinforcing existing treatment guidelines.
Article Synopsis
- Cancer-associated venous thromboembolism (CAT) guidelines suggest using direct oral anticoagulants like rivaroxaban as alternatives to low-molecular-weight heparin (LMWH) for most patients.
- This study analyzed data from nearly 5,000 patients with active cancer experiencing acute venous thromboembolism (VTE) and found that rivaroxaban led to fewer recurrent VTE incidents compared to LMWH at 3 months.
- Both treatment options showed similar rates of bleeding-related hospitalizations and all-cause mortality, indicating that rivaroxaban may be a safer and more effective choice in this cohort.